Insider Selling: Caribou Biosciences, Inc. (NASDAQ:CRBU) Insider Sells 5,627 Shares of Stock

Caribou Biosciences, Inc. (NASDAQ:CRBUGet Rating) insider Syed Ali-Aamir Rizvi sold 5,627 shares of the company’s stock in a transaction dated Thursday, January 19th. The shares were sold at an average price of $6.31, for a total transaction of $35,506.37. Following the completion of the sale, the insider now directly owns 59,373 shares of the company’s stock, valued at $374,643.63. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Caribou Biosciences Trading Up 1.6 %

Shares of NASDAQ CRBU opened at $6.39 on Monday. Caribou Biosciences, Inc. has a twelve month low of $4.89 and a twelve month high of $13.19. The company has a market capitalization of $389.80 million, a price-to-earnings ratio of -4.23 and a beta of 1.85. The firm has a 50-day moving average of $7.76 and a two-hundred day moving average of $8.93.

Caribou Biosciences (NASDAQ:CRBUGet Rating) last posted its quarterly earnings data on Tuesday, November 8th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.04. The firm had revenue of $3.30 million for the quarter, compared to the consensus estimate of $3.63 million. Caribou Biosciences had a negative return on equity of 26.66% and a negative net margin of 714.82%. As a group, research analysts predict that Caribou Biosciences, Inc. will post -1.73 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Citigroup cut their price target on shares of Caribou Biosciences from $38.00 to $37.00 in a report on Wednesday, November 23rd. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Caribou Biosciences presently has an average rating of “Buy” and an average price target of $27.80.

Institutional Trading of Caribou Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of CRBU. Elmwood Wealth Management Inc. acquired a new stake in Caribou Biosciences during the 3rd quarter worth about $24,943,000. State Street Corp raised its holdings in Caribou Biosciences by 200.3% during the 3rd quarter. State Street Corp now owns 2,395,470 shares of the company’s stock worth $25,272,000 after buying an additional 1,597,870 shares during the period. BlackRock Inc. raised its holdings in Caribou Biosciences by 88.3% during the 1st quarter. BlackRock Inc. now owns 3,319,182 shares of the company’s stock worth $30,470,000 after buying an additional 1,556,153 shares during the period. Assenagon Asset Management S.A. acquired a new stake in Caribou Biosciences during the 2nd quarter worth about $6,027,000. Finally, Vanguard Group Inc. raised its holdings in Caribou Biosciences by 118.9% during the 1st quarter. Vanguard Group Inc. now owns 2,001,554 shares of the company’s stock worth $18,375,000 after buying an additional 1,087,038 shares during the period. Institutional investors and hedge funds own 70.44% of the company’s stock.

About Caribou Biosciences

(Get Rating)

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma.

Read More

Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with's FREE daily email newsletter.